Skip to main content
Equibles
ADXN logo

ADXN · Addex Therapeutics Ltd.

Track ADXN — free

Use ADXN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ADXN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$5.95 At close · Aug 10
Market Cap
$7.34M
Shares
1.27M

Addex Therapeutics Ltd. Earnings Call Transcripts

Every quarterly earnings call for Addex Therapeutics Ltd. (ADXN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY25 · Q3
2025-09-30
Addex Therapeutics Ltd. Q3 FY2025 Earnings Call
Positive tone Dipraglurant post-stroke / brain injury recovery GABAB PAM chronic cough program Neurosterix spin-out
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Addex Therapeutics Ltd. Q2 FY2025 Earnings Call
Positive tone GABAB PAM chronic cough program Neurosterix spin-out and M4 PAM progress Financing need for IND-enabling studies
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Addex Therapeutics Ltd. Q1 FY2025 Earnings Call
Confident tone GABAB PAM for chronic cough Dipraglurant repositioning for brain injury recovery Indivior partnership for substance use disorders
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-09-30
Addex Therapeutics Ltd. Q3 FY2024 Earnings Call
Confident tone GABAB PAM program for chronic cough Neurosterix spin-out and M4 PAM program Financial position and cash runway
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Addex Therapeutics Ltd. Q2 FY2024 Earnings Call
Positive tone GABAB PAM chronic cough program GABAB PAM substance use disorders (Indivior partnership) Neurosterix spin-out / Series A financing
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Addex Therapeutics Ltd. Q1 FY2024 Earnings Call
Positive tone GABAB PAM collaboration with Indivior Neurosterix financing transaction and 20% equity stake M4 PAM program for schizophrenia (via Neurosterix)
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Addex Therapeutics Ltd. Q4 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q2
2023-06-30
Addex Therapeutics Ltd. Q2 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Addex Therapeutics Ltd. Q1 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Addex Therapeutics Ltd. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Addex Therapeutics Ltd. Q3 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Addex Therapeutics Ltd. Q2 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Addex Therapeutics Ltd. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Addex Therapeutics Ltd. Q3 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Addex Therapeutics Ltd. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–15 of 15 earnings calls
Key facts CIK 1574232 CUSIP 00654J206 13F (30d) 2 filings 2 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)